Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia

Jyoti Malhotra1, Marina Kremyanskaya1, Emily Schorr1

  • 1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

Abstract

Insights

Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) can coexist with plasma-cell disorders like multiple myeloma (MM). Management focuses on treating the MPN and monitoring for MM transformation.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), involve clonal hematopoietic cell proliferation.
  • Coexistence of MPNs with plasma-cell diseases such as multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) has been reported.

Observation:

  • A study reviewed 15 patients diagnosed with both MPN and MGUS or MM over a 5-year period.
  • The majority of patients (12/15) received their MPN diagnosis before or concurrently with their MGUS/MM diagnosis.
  • No treatment-related effects were identified as contributing to the development of coexisting MGUS/MM and MPN.

Findings:

  • Two patients developed lymphoid leukemia, one developed lymphoma, and one developed acute myeloid leukemia, prompting investigation into increased transformation risk in coexisting myeloid and lymphoid neoplasms.
  • Among 7 patients with abnormal karyotypes, 3 exhibited trisomy 8.
  • The origin of these coexisting conditions from a common hematopoietic stem cell remains unproven.

Implications:

  • Current management involves treating the MPN and monitoring MGUS for progression to overt malignancy.
  • For patients with overt MM, treatment prioritizes myeloma management while monitoring the MPN.
  • Further research is needed to elucidate the pathogenesis and optimal management strategies for these coexisting hematologic malignancies.

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.3K
Cellular Adaptation IV: Dysplasia and Metaplasia01:24

Cellular Adaptation IV: Dysplasia and Metaplasia

DysplasiaDysplasia refers to abnormal changes in the size, shape, and organization of mature cells, characterized by pleomorphism, nuclear abnormalities, and increased mitotic activity. It commonly affects epithelial tissues, including the cervix, gastrointestinal tract, respiratory mucosa, and endometrium. Although it may occur alongside hyperplasia, dysplasia is not a true adaptive response but a preneoplastic change with potential to progress to cancer.When confined above the basement...
70
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
3.4K